<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epoetin alfa (including biosimilars): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epoetin alfa (including biosimilars): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Epoetin alfa (including biosimilars): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11639" href="/d/html/11639.html" rel="external">see "Epoetin alfa (including biosimilars): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13273" href="/d/html/13273.html" rel="external">see "Epoetin alfa (including biosimilars): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708743"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular events:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Erythropoiesis-stimulating agents (ESAs) increase the risk of death, MI, stroke, venous thromboembolism, thrombosis of vascular access.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Chronic kidney disease:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered ESAs to target a hemoglobin level of greater than 11 g/dL. No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks. Use the lowest epoetin alfa dose sufficient to reduce the need for RBC transfusions.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cancer:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers. To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC transfusions. Use ESAs only for anemia from myelosuppressive chemotherapy. ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure. Discontinue following the completion of a chemotherapy course.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Perisurgery:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Due to increased risk of DVT, DVT prophylaxis is recommended.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F165764"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Epogen;</li>
<li>Procrit;</li>
<li>Retacrit</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866746"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Eprex</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F165808"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Colony Stimulating Factor;</li>
<li>
                        Erythropoiesis-Stimulating Agent (ESA);</li>
<li>
                        Hematopoietic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F165767"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Doses are often rounded to the nearest unit dose (eg, a vial or combination of vials) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berns.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berns.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information: </b>Retacrit (epoetin alfa-epbx) is approved as a biosimilar to Epogen (epoetin alfa) and Procrit (epoetin alfa).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Ensure adequate iron stores before initiating and throughout therapy. The manufacturer recommends supplemental iron be administered if serum ferritin is &lt;100 ng/mL or serum transferrin saturation is &lt;20%; however, the threshold for iron replacement should be individualized based on clinical considerations (eg, trends in Hb level, epoetin alfa dose, goals of therapy) and may vary by indication. Most patients with chronic kidney disease (CKD) will require iron supplementation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1','lexi-content-ref-manu.1'])">Ref</a></span>).<b></b></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3116dd61-6cba-41fb-87e5-254391beb8f2">Anemia due to chemotherapy in patients with cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anemia due to chemotherapy in patients with cancer:</b> Initiate treatment only if Hb &lt;10 g/dL and anticipated duration of myelosuppressive chemotherapy is at least 2 additional months. Titrate dosage to use the minimum effective dose that will maintain a Hb level sufficient to avoid RBC transfusions. Discontinue erythropoietin following completion of chemotherapy. <b>SUBQ:</b> Initial dose: 150 units/kg 3 times a week or 40,000 units once weekly until completion of chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dosage adjustments:</i></p>
<p style="text-indent:-2em;margin-left:6em;">If Hb does not increase by ≥1 g/dL <b>and</b> remains below 10 g/dL after initial 4 weeks: Increase to 300 units/kg 3 times a week or 60,000 units weekly; discontinue after 8 weeks of treatment if RBC transfusions are still required or there is no Hb response.</p>
<p style="text-indent:-2em;margin-left:6em;">If Hb exceeds a level needed to avoid RBC transfusion: Withhold dose; resume treatment with a 25% dose reduction when Hb approaches a level where transfusions may be required.</p>
<p style="text-indent:-2em;margin-left:6em;">If Hb increases &gt;1 g/dL in any 2-week period <b>or</b> Hb reaches a level sufficient to avoid RBC transfusion: Reduce dose by 25%.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="41d04c29-d2e2-40fe-8ef8-0f987c725559">Anemia due to chronic kidney disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anemia due to chronic kidney disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Generally initiated when Hb is &lt;10 g/dL; however, the decision to initiate therapy must be individualized based on patient-specific factors (eg, rate of Hb decline, risks of repeat RBC transfusion, symptom severity) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial dose: </b>Individualize initial dose within ranges shown below according to baseline Hb concentration and risk of adverse effects (eg, cardiovascular) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1','lexi-content-ref-manu.1'])">Ref</a></span>). An optimal initial dosing algorithm has not been established; refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients with chronic kidney disease <b>ON dialysis:</b></i>
<b>IV, SUBQ:</b> 20 to 50 units/kg 3 times per week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1'])">Ref</a></span>); in some patients with lower initial Hb levels (eg, &lt;8 g/dL), an initial dose of up to 100 units/kg 3 times per week may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berns.2','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berns.2','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients with chronic kidney disease <b>NOT on dialysis:</b></i>
<b>IV, SUBQ (preferred route):</b> 50 to 100 units/kg every 1 to 2 weeks; typical initial regimens include 4,000 to 10,000 units once weekly <b>or</b> 10,000 to 20,000 units every other week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berns.1','lexi-content-ref-29336855','lexi-content-ref-18417741','lexi-content-ref-12455725','lexi-content-ref-15224803']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berns.1','lexi-content-ref-29336855','lexi-content-ref-18417741','lexi-content-ref-12455725','lexi-content-ref-15224803'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> The initial doses recommended above are generally lower than those recommended in the manufacturer’s labeling. Due to safety concerns, lower doses are typically preferred according to clinical practice and guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30675430','lexi-content-ref-29336855','lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30675430','lexi-content-ref-29336855','lexi-content-ref-KDIGO.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage adjustment: </b>Use the lowest maintenance dose necessary to reduce the need for RBC transfusions and manage symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1','lexi-content-ref-manu.1'])">Ref</a></span>). Target Hb range suggested by KDIGO is 10 to 11.5 g/dL, while manufacturer’s labeling recommends a range of 10 to 11 g/dL for patients on dialysis and not exceeding 10 g/dL for patients not on dialysis. Target should be individualized for anticipated benefits and risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1','lexi-content-ref-manu.1'])">Ref</a></span>). An optimal dosage adjustment algorithm has not been identified. The following provides general guidance; refer also to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>If Hb does not increase by &gt;1 g/dL after 4 weeks: </i>Increase dose by 25%; do not increase dose more frequently than once every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> In patients who have no Hb response after adequate titration (generally over 4 to 12 weeks), or who have not met Hb targets despite high doses (eg, ≥450 units/kg per week IV or ≥300 units/kg per week SUBQ) in the presence of adequate iron stores, reassess for other underlying causes of anemia; further dose increases are unlikely to improve response and may increase cardiovascular risks and mortality (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1','lexi-content-ref-11229970','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1','lexi-content-ref-11229970','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>If Hb increases by &gt;1 g/dL in any 2-week period or &gt;2 g/dL in any 4-week period:</i> Reduce dose by 25% to 50% or hold therapy depending on Hb level and rate of increase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29336855','lexi-content-ref-KDIGO.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29336855','lexi-content-ref-KDIGO.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>If Hb is increasing and approaching the upper target threshold:</i> Reduce dose by 25%; if Hb continues to increase, hold therapy until Hb begins to decrease and then reinitiate at 75% of the previous dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Loss of efficacy (ie, acquired hyporesponsiveness): </b>If an acute Hb decrease occurs in a patient who previously achieved target Hb levels on a stable epoetin dose, identify and treat underlying cause for acute Hb decrease prior to adjusting epoetin dose. If patient remains hyporesponsive, may cautiously use the minimum epoetin dose to avoid RBC transfusions; refer also to institutional protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4460e6e2-eb92-4034-b181-06892f01fa8a">Anemia due to zidovudine in HIV-infected patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anemia due to zidovudine in HIV-infected patients:</b> Titrate dosage to use the minimum effective dose that will maintain a Hb level sufficient to avoid RBC transfusions. Hb levels should not exceed 12 g/dL.</p>
<p style="text-indent:-2em;margin-left:4em;">Serum erythropoietin levels ≤500 milliunits/mL and zidovudine doses ≤4,200 mg/week): <b>IV, SUBQ:</b> Initial: 100 units/kg 3 times a week; if Hb does not increase after 8 weeks, increase dose by ~50 to 100 units/kg at 4 to 8 week intervals until Hb reaches a level sufficient to avoid RBC transfusion; maximum dose: 300 units/kg. Withhold dose if Hb exceeds 12 g/dL, may resume treatment with a 25% dose reduction once Hb &lt;11 g/dL. Discontinue if Hb increase is not achieved with 300 units/kg for 8 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7c5cccca-b60d-4c11-86cb-c8202712a93e">Myelodysplastic syndromes, lower-risk, symptomatic anemia management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myelodysplastic syndromes, lower-risk, symptomatic anemia management (off-label use):</b>
<b>SUBQ:</b> 150 to 300 units/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19564636']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19564636'])">Ref</a></span>) <b>or</b> 450 units/kg (up to 40,000 units/dose) once weekly; based on erythroid response after 8 weeks may increase to 1,050 units/kg (up to 80,000 units/dose) once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29895954']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29895954'])">Ref</a></span>) <b>or </b>450 to 1,000 units/kg/week in divided doses, 3 to 7 times a week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7833279']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7833279'])">Ref</a></span>) <b>or</b> 40,000 units once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12846896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12846896'])">Ref</a></span>) <b>or</b> 60,000 units once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17940203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17940203'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="de3a7427-5232-4af2-8738-6d1e44d49d56">Reduction of allogeneic RBC transfusion in patients undergoing elective, noncardiac, nonvascular surgery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reduction of allogeneic RBC transfusion in patients undergoing elective, noncardiac, nonvascular surgery</b> (perioperative Hb should be &gt;10 g/dL and ≤13 g/dL; DVT prophylactic anticoagulation is recommended): <b>SUBQ:</b> Initial dose:</p>
<p style="text-indent:-2em;margin-left:4em;">300 units/kg/day for 15 days total, beginning 10 days before surgery, on the day of surgery, and for 4 days after surgery <b>or</b></p>
<p style="text-indent:-2em;margin-left:4em;">600 units/kg once weekly for 4 doses, given 21-, 14-, and 7 days before surgery, and on the day of surgery.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="da906abc-9c9c-4eca-909c-2205e2602c09">RBC transfusion refusal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>RBC transfusion refusal (substitute) (off-label use): Note:</b> Concomitantly administer iron (with or without vitamin B<sub>12</sub> and folic acid supplementation) with epoetin alfa and use in conjunction with other blood conservation techniques.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Spinal (elective) surgery:</i>
<b>SUBQ:</b> 40,000 units weekly for 4 weeks prior to surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18827697']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18827697'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cardiac (elective) surgery:</i></p>
<p style="text-indent:-2em;margin-left:6em;">One protocol based on timing of elective surgery and preoperative Hb used the following (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24809815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24809815'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;21 days until surgery:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Hb &lt;10 g/dL:</i> Delay surgery; identify cause of anemia.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Hb 10 to 12 g/dL:</i>
<b>SUBQ:</b> 40,000 units (if &lt;65 kg, use 600 units/<b>kg</b>/dose) weekly starting 21 days before surgery.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Hb &gt;12 to &lt;13 g/dL</i>: <b>SUBQ:</b> 40,000 units (if &lt;65 kg, use 600 units/<b>kg</b>/dose) weekly starting 10 days before surgery and repeat 3 days before surgery or on the morning of surgery.</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;21 days until surgery:</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Hb &lt;10 g/dL:</i> Delay surgery; identify cause of anemia.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Hb 10 to 12 g/dL:</i>
<b>SUBQ:</b> 20,000 units (if &lt;65 kg, use 300 units/<b>kg</b>/dose) daily starting up to 10 days before surgery, on the day of surgery, and 4 days postoperatively if necessary.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Hb &gt;12 to &lt;13 g/dL</i>: <b>SUBQ:</b> 20,000 units (if &lt;65 kg, use 300 units/<b>kg</b>/dose) daily starting up to 10 days before surgery, on the day of surgery, and 4 days postoperatively if necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Another protocol utilized weight-based dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26211405']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26211405'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Preoperative:</i></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV:</b> 200 units/kg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>SUBQ:</b> 250 to 500 units/kg every 48 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> Timing prior to surgery was not described; target Hb of 12 g/dL.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Postoperative:</i></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV:</b> 200 to 300 units/kg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>SUBQ:</b> 250 to 500 units/kg every 48 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> Target Hb &gt;10 g/dL.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990638"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2505184','lexi-content-ref-2029809']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2505184','lexi-content-ref-2029809'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8808454']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8808454'])">Ref</a></span>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2505184','lexi-content-ref-2029809','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2505184','lexi-content-ref-2029809','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2488207','lexi-content-ref-2563798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2488207','lexi-content-ref-2563798'])">Ref</a></span>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2029809','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2029809','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987797"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F165768"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F165789"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13273" href="/d/html/13273.html" rel="external">see "Epoetin alfa (including biosimilars): Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Dosing schedules need to be individualized and careful monitoring of patients receiving the drug is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Use has not been demonstrated in controlled clinical trials to improve symptoms of anemia, quality of life, fatigue, or patient well-being.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="61754c96-8ce8-42e3-adb4-ccbe7f09baad">Anemia in chronic kidney disease, ON dialysis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anemia in chronic kidney disease, ON dialysis: Note:</b> The IV route is preferred for hemodialysis patients; initiate treatment when hemoglobin is &lt;10 g/dL; reduce dose or interrupt treatment if hemoglobin approaches or exceeds 12 g/dL (if age ≤16 years) or 11 g/dL (if age &gt;16 years):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial dose:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents ≤16 years: IV, SubQ: 50 units/kg/dose 3 times weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents &gt;16 years: IV, SubQ: 50 to 100 units/kg/dose 3 times weekly.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dosage adjustments: </i>IV, SubQ:</p>
<p style="text-indent:-2em;margin-left:6em;">If hemoglobin does <b>not</b> increase by &gt;1 g/dL after 4 weeks: Increase dose by 25%; do not increase the dose more frequently than once every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">If hemoglobin increases &gt;1 g/dL in any 2-week period: Reduce dose by ≥25%; dose reductions can occur more frequently than once every 4 weeks; avoid frequent dosage adjustments.</p>
<p style="text-indent:-2em;margin-left:6em;">Inadequate or lack of response over a 12-week escalation period: Further increases are unlikely to improve response and may increase risks; use the minimum effective dose that will maintain an Hgb level sufficient to avoid RBC transfusions and evaluate patient for other causes of anemia. Discontinue therapy if responsiveness does not improve.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d17b807a-964f-4bef-afaa-5d331aa25525">Anemia in chronic kidney disease, NO dialysis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anemia in chronic kidney disease, NO dialysis:</b>
<b>Note:</b> Consider initiating treatment when hemoglobin is &lt;10 g/dL; use only if rate of hemoglobin decline would likely result in RBC transfusion and desire is to reduce risk of alloimmunization or other RBC transfusion-related risks; reduce dose or interrupt treatment if hemoglobin exceeds 12 g/dL (if age ≤16 years) or 10 g/dL (if age &gt;16 years):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial dose:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents ≤16 years: IV, SubQ: 50 units/kg/dose 3 times weekly</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents &gt;16 years: IV, SubQ: 50 to 100 units/kg/dose 3 times weekly</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dosage adjustments</i>: IV, SubQ:</p>
<p style="text-indent:-2em;margin-left:6em;">If hemoglobin does <b>not</b> increase by &gt;1 g/dL after 4 weeks: Increase dose by 25%; do not increase the dose more frequently than once every 4 weeks</p>
<p style="text-indent:-2em;margin-left:6em;">If hemoglobin increases &gt;1 g/dL in any 2-week period: Reduce dose by ≥25%; dose reductions can occur more frequently than once every 4 weeks; avoid frequent dosage adjustments</p>
<p style="text-indent:-2em;margin-left:6em;">Inadequate or lack of response over a 12-week escalation period: Further increases are unlikely to improve response and may increase risks; use the minimum effective dose that will maintain a Hgb level sufficient to avoid RBC transfusions and evaluate patient for other causes of anemia. Discontinue therapy if responsiveness does not improve.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d404936-739a-4a5c-928d-f82bdc794398">Anemia due to myelosuppressive chemotherapy in cancer patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anemia due to myelosuppressive chemotherapy in cancer patients:</b>
<b>Note:</b> Initiate treatment only if hemoglobin &lt;10 g/dL and anticipated duration of myelosuppressive chemotherapy is ≥2 months.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial dose:</i> IV: 600 units/kg/dose once weekly until completion of chemotherapy; titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid red blood cell transfusions.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage adjustments: </i>IV:</p>
<p style="text-indent:-2em;margin-left:8em;">If hemoglobin does not increase by &gt;1 g/dL <b>and</b> remains &lt;10 g/dL after initial 4 weeks: Increase to 900 units/kg/dose (maximum dose: 60,000 units/dose); discontinue after 8 weeks of treatment if RBC transfusions are still required or there is no hemoglobin response</p>
<p style="text-indent:-2em;margin-left:8em;">If hemoglobin exceeds a level needed to avoid red blood cell transfusion: Withhold dose; resume treatment with a 25% dose reduction when hemoglobin approaches a level where transfusions may be required</p>
<p style="text-indent:-2em;margin-left:8em;">If hemoglobin increases &gt;1 g/dL in any 2-week period <b>or</b> hemoglobin reaches a level sufficient to avoid red blood cell transfusion: Reduce dose by 25%</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4460e6e2-eb92-4034-b181-06892f01fa8a">Anemia due to zidovudine in HIV-infected patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anemia due to zidovudine in HIV-infected patients:</b> Limited data available: <b>Note: </b>Epoetin alfa is not described as a therapeutic option for management of anemia in pediatric HIV patients on zidovudine therapy; experts suggest discontinuing zidovudine and switching to an anti-retroviral regimen that does not contain zidovudine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months, Children, and Adolescents ≤17 years: IV, SubQ: Doses ranging from 50 to 400 units/kg/dose 2 to 3 times weekly have been reported; withhold dose if hemoglobin exceeds 12 g/dL, may resume treatment with a 25% dose reduction once hemoglobin &lt;11 g/dL; titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid red blood cell transfusions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11828859']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11828859'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51108595"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: No dosage adjustment necessary.</p></div>
<div class="block dohp drugH1Div" id="F51108596"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F165731"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (6% to 28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (5% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (16% to 21%), skin rash (2% to 19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (35% to 56%), vomiting (19% to 28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site pain (9% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (10% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (4% to 26%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (10% to 42%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Thrombosis of hemodialysis vascular access (8%), thrombosis (≤6%), deep vein thrombosis (5% to 6%), edema (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (10%), chills (4% to 7%), insomnia (6%), depression (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (9%), hyperglycemia (6%), hypokalemia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Stomatitis (10%), dysphagia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Irritation at injection site (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (10%), muscle spasm (7%), ostealgia (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (7%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Antibody development (neutralizing), cardiac failure, cerebrovascular accident, erythema, erythema multiforme, exfoliation of skin, hypertensive encephalopathy, myocardial infarction, porphyria, pure red cell aplasia, seizure, severe anemia, skin blister, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>
<div class="block coi drugH1Div" id="F165745"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Serious allergic reactions to epoetin alfa products or any component of the formulations; uncontrolled hypertension; pure red cell aplasia (PRCA) that begins after treatment with epoetin alfa or other epoetin protein drugs; multidose vials contain benzyl alcohol and are contraindicated in neonates, infants, pregnant women, and breastfeeding women</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindications (not in the US labelings): Known hypersensitivity to mammalian cell-derived products or any component of the formulation; patients who for any reason cannot receive adequate antithrombotic treatment; use in patients with severe coronary, peripheral arterial, carotid, or cerebral vascular disease, including patients with recent MI or cerebral vascular accident scheduled for elective surgery and not participating in an autologous blood donation program.</p></div>
<div class="block war drugH1Div" id="F165728"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular events: <b>[US Boxed Warning]: Erythropoiesis-stimulating agents (ESAs) increased the risk of serious cardiovascular events, myocardial infarction (MI), stroke, venous thromboembolism (VTE), vascular access thrombosis, and mortality in clinical studies when administered to target Hb levels &gt;11 g/dL</b> (and provide no additional benefit); a rapid rise in Hb (&gt;1 g/dL over 2 weeks) may also contribute to these risks.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cutaneous reactions: Erythema multiforme and Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) have been reported with ESAs (including epoetin alfa products); discontinue immediately if a severe cutaneous reaction develops.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Potentially serious allergic reactions (including anaphylactic reactions, angioedema, bronchospasm, rash, and urticaria) have been reported rarely with epoetin alfa. Discontinue immediately (and permanently) in patients who experience serious allergic/anaphylactic reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pure red cell aplasia (PRCA): Cases of severe anemia and PRCA have been reported, predominantly in patients with chronic kidney disease (CKD) receiving SUBQ epoetin alfa; cases have also been reported in patients with hepatitis C who were receiving ESAs, interferon, and ribavirin. Patients with a sudden loss of response (with severe anemia and a low reticulocyte count) should be evaluated for PRCA with associated neutralizing antibodies to erythropoietin; discontinue treatment (permanently) in patients with PRCA secondary to neutralizing antibodies to erythropoietin. Information on assays for binding and neutralizing antibodies may be obtained from the manufacturer of the specific epoetin alfa product used. Antibodies may cross-react; do not switch to another ESA in patients who develop antibody-mediated anemia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cancer: <b>[US Boxed Warning]: A shortened overall survival and/or increased risk of tumor progression or recurrence has been reported in studies with breast, cervical, head and neck, lymphoid, and non-small cell lung cancer patients.</b> It is of note that in most of these studies, patients received ESAs to a target Hb of ≥12 g/dL; although risk has not been excluded when dosed to achieve a target Hb of &lt;12 g/dL. <b>[US Boxed Warnings]: To decrease these risks, and risk of cardio and thrombovascular events, use the lowest dose needed to avoid RBC transfusions. Use ESAs in cancer patients only for the treatment of anemia related to concurrent myelosuppressive chemotherapy; discontinue ESA following completion of the chemotherapy course. ESAs are <span style="text-decoration: underline">not</span> indicated for patients receiving myelosuppressive therapy when the anticipated outcome is curative.</b> A dosage modification is appropriate if Hb levels rise &gt;1 g/dL per 2-week time period during ESA treatment (ASCO/ASH [Bohlius 2019]). Use of ESAs has been associated with an increased risk of VTE without a reduction in transfusions in patients &gt;65 years of age with cancer (Hershman 2009). Improved anemia symptoms, quality of life, fatigue, or well-being have not been demonstrated in controlled clinical trials.</p>
<p style="text-indent:-2em;margin-left:4em;">• Chronic kidney disease: <b>[US Boxed Warning]: An increased risk of death, serious cardiovascular events, and stroke was reported in CKD patients administered ESAs to target Hb levels &gt;11 g/dL; use the lowest dose sufficient to reduce the need for RBC transfusions. An optimal target Hb level, dose or dosing strategy to reduce these risks has not been identified in clinical trials.</b> Hb rising &gt;1 g/dL in a 2-week period may contribute to the risk (dosage reduction recommended). CKD patients who exhibit an inadequate Hb response to ESA therapy may be at a higher risk for cardiovascular events and mortality compared to other patients. ESA therapy may reduce dialysis efficacy (due to increase in RBCs and decrease in plasma volume); adjustments in dialysis parameters may be needed. Patients treated with epoetin alfa may require increased heparinization during dialysis to prevent clotting of the extracorporeal circuit.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes mellitus: ESAs may artificially lower HbA<sub>1c</sub> through increased circulation of immature erythrocytes in the peripheral blood stream (Kobayashi 2016; Rasche 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Avoid use; erythrocyte stimulating agents do not provide clinical benefit and may increase risk of thrombotic events, including stroke (AHA/ACC/HFSA [Heidenreich 2022]; Kang 2016; Swedberg 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertension: Use with caution in patients with a history of hypertension (contraindicated in uncontrolled hypertension). An excessive rate of rise of Hb is associated with hypertension or exacerbation of hypertension; decrease the epoetin alfa dose if the Hb increase exceeds 1 g/dL in any 2-week period. BP should be controlled prior to start of therapy and monitored closely throughout treatment. Hypertensive encephalopathy has been reported with patients receiving erythropoietic therapy; monitor closely and control BP.</p>
<p style="text-indent:-2em;margin-left:4em;">• Perisurgery: <b>[US Boxed Warning]: Deep vein thrombosis (DVT) prophylaxis is recommended in perisurgery patients due to the increased risk of DVT. </b> Increased mortality was also observed in patients undergoing coronary artery bypass surgery who received epoetin alfa; these deaths were associated with thrombotic events. Epoetin alfa is <b>not</b> approved for reduction of RBC transfusion in patients undergoing cardiac or vascular surgery and is <b>not</b> indicated for surgical patients willing to donate autologous blood.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: The risk for seizures is increased with epoetin alfa product use in patients with CKD; use with caution in patients with a history of seizures. Monitor closely for neurologic symptoms during the first several months of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Severe anemia or acute blood loss: Due to the delayed onset of erythropoiesis, epoetin alfa is not recommended for acute correction of severe anemia or as a substitute for emergency transfusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage form specific issues:</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Albumin: Product may contain albumin, which confers a theoretical risk of transmission of viral disease or Creutzfeldt-Jakob disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: Some dosage forms may contain phenylalanine, which may be harmful in patients with phenylketonuria. Consider the combined daily phenylalanine amount from all sources prior to prescribing products containing phenylalanine (and aspartame).</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use:</p>
<p style="text-indent:-2em;margin-left:6em;">- Oncology: The American Society of Clinical Oncology and American Society of Hematology 2019 updates to the clinical practice guidelines for the use of ESAs in adult patients with cancer indicate that ESAs are appropriate when used according to the parameters identified within the FDA-approved labeling for epoetin alfa and darbepoetin alfa (ASCO/ASH [Bohlius 2019]). ESAs are an option for chemotherapy-associated anemia in patients whose cancer treatment is not of curative intent and when the Hb has fallen to &lt;10 g/dL. ESAs should not be used when the intent of cancer chemotherapy is curative. ESAs should only be used in conjunction with concurrent myelosuppressive chemotherapy (except in the case of low-risk myelodysplastic syndromes). For patients with myeloma, non-Hodgkin lymphoma, or chronic lymphocytic leukemia, observe hematologic response to cancer treatment prior to considering an ESA. Consider risks versus benefits when there is an increased risk of thromboembolic complications. The recommended target Hb level is the lowest Hb concentration necessary to avoid or reduce the need for RBC transfusion. ESAs should be discontinued in patients who do not respond (eg, &lt;1 to 2 g/dL increase in Hb or no reduction in RBC transfusions within 6 to 8 weeks [evaluate nonresponders for underlying tumor progression, iron deficiency, or other causes of anemia]). Iron replacement may be utilized to improve Hb response or reduce RBC transfusions in patients with and without iron deficiency receiving ESAs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Factors impairing erythropoiesis: Prior to treatment, correct or exclude deficiencies of iron, vitamin B<sub>12</sub>, and/or folate, as well as other factors that may impair erythropoiesis (inflammatory conditions, infections, bleeding). Poor response to therapy should prompt evaluation of potential factors impairing erythropoiesis, as well as possible malignant processes and hematologic disease (thalassemia, refractory anemia, myelodysplastic disorder), occult blood loss, hemolysis, osteitis fibrosa cystic, and/or bone marrow fibrosis.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878444"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">May be associated with an increased risk of retinopathy of prematurity (ROP); an increase in ROP has been observed in neonates receiving epoetin alfa for anemia of prematurity, with a reported incidence of 15% to 17%; however, a direct association with the drug has not been established. A meta-analysis of early treatment with epoetin alfa showed that neonates treated within the first week of life did not have a significant increased incidence in stage ≥3 ROP; however, a post-ad hoc data analysis of all neonates (regardless of age at treatment) showed an increased risk (Ohlsson 2014); a meta-analysis of late treatment showed an overall trend toward increased incidence of ROP (all stages) and at stage ≥3 (Aher 2014). A phase 3 randomized, placebo-controlled trial of the use of high-dose erythropoietin in extremely preterm infants showed no significant difference between treatment and placebo groups for the incidence of ROP (Juul 2020). Risks and benefits should be assessed prior to initiation.</p></div>
<div class="block foc drugH1Div" id="F165738"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Epogen: 10,000 units/mL (2 mL); 20,000 units/mL (1 mL) [contains albumin human, benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Procrit: 10,000 units/mL (2 mL); 20,000 units/mL (1 mL) [contains albumin human, benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Retacrit: Epoetin Alfa-epbx 10000 units/mL (2 mL); Epoetin Alfa-epbx 20000 units/mL (1 mL) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Epogen: 2000 units/mL (1 mL); 3000 units/mL (1 mL); 4000 units/mL (1 mL); 10,000 units/mL (1 mL) [contains albumin human]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Procrit: 2000 units/mL (1 mL); 3000 units/mL (1 mL); 4000 units/mL (1 mL); 10,000 units/mL (1 mL); 40,000 units/mL (1 mL) [contains albumin human]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Retacrit: Epoetin Alfa-epbx 2000 units/mL (1 mL); Epoetin Alfa-epbx 3000 units/mL (1 mL); Epoetin Alfa-epbx 4000 units/mL (1 mL); Epoetin Alfa-epbx 10000 units/mL (1 mL); Epoetin Alfa-epbx 40000 units/mL (1 mL) [contains phenylalanine]</p></div>
<div class="block geq drugH1Div" id="F165724"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F165748"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Epogen Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000 units/mL (per mL): $39.79</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3000 units/mL (per mL): $59.69</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4000 units/mL (per mL): $79.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10000 units/mL (per mL): $198.96</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20000 units/mL (per mL): $397.92</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Procrit Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000 units/mL (per mL): $64.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3000 units/mL (per mL): $96.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4000 units/mL (per mL): $128.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10000 units/mL (per mL): $320.70</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20000 units/mL (per mL): $641.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40000 units/mL (per mL): $1,282.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Retacrit Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000 units/mL (per mL): $26.47</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3000 units/mL (per mL): $39.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4000 units/mL (per mL): $52.94</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10000 units/mL (per mL): $132.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20000 units/mL (per mL): $264.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40000 units/mL (per mL): $529.44</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866747"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Eprex: 6000 units/0.6 mL (0.6 mL); 20,000 units/0.5 mL (0.5 mL); 40,000 units/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Eprex: 1000 units/0.5 mL (0.5 mL); 2000 units/0.5 mL (0.5 mL); 3000 units/0.3 mL (0.3 mL); 4000 units/0.4 mL (0.4 mL); 5000 units/0.5 mL (0.5 mL); 8000 units/0.8 mL (0.8 mL); 10,000 units/mL (1 mL); 30,000 units/0.75 mL (0.75 mL)</p></div>
<div class="block adm drugH1Div" id="F165742"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> SUBQ is the preferred route of administration <b>except</b> in patients with chronic kidney disease (CKD) on hemodialysis. In patients with CKD on hemodialysis, the IV or SUBQ route can be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1'])">Ref</a></span>). Do not shake.</p>
<p style="text-indent:-2em;margin-left:2em;">Epogen, Procrit: Usually administered undiluted, although preservative-free (single-dose vial) formulations may be diluted in a syringe prior to administration as a 1:1 dilution using bacteriostatic NS.</p>
<p style="text-indent:-2em;margin-left:2em;">Retacrit: Do not dilute.</p></div>
<div class="block admp drugH1Div" id="F52612700"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Do not shake as this may denature the glycoprotein rendering the drug biologically inactive; do not use if product has been shaken or frozen.</p>
<p style="text-indent:-2em;margin-left:2em;">SubQ: Administer into the outer upper arm, abdomen (except within 2 inches of navel), front middle thigh, or the upper outer buttocks area. Rotate injection site; do not inject into areas that are tender, red, bruised, hardened, or scarred, or sites with stretch marks.</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates and Infants: Use single-dose vials only to provide doses; limits exposure to benzyl alcohol and potential toxicity. Do not mix with bacteriostatic NS.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Epogen, Procrit: Usually administered undiluted; preservative-free solutions may be mixed with bacteriostatic NS at time of administration to reduce pain at injection site. Multiple-dose vials already contain benzyl alcohol.</p>
<p style="text-indent:-2em;margin-left:6em;">Retacrit: Do not dilute.</p>
<p style="text-indent:-2em;margin-left:2em;">IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Only use single-dose preservative-free formulations; limits exposure to benzyl alcohol and potential toxicity. Based on studies evaluating use in neonates for neuroprotection/hypoxic ischemia encephalopathy, administer peripherally or centrally as bolus injection over &lt;2 minutes; may follow with NS flush through the most proximal port; flush volume ≥3 times the line volume (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18676557','lexi-content-ref-19651565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18676557','lexi-content-ref-19651565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Administer by IV bolus; usually administered undiluted; preservative-free solutions may be mixed with bacteriostatic NS at time of administration; may be administered into the hemodialysis line. <b>Note:</b> For infant doses, only use preservative-free single-use formulations; limits exposure to benzyl alcohol and potential toxicity.</p></div>
<div class="block meg drugH1Div" id="F7874643"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Epogen: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F103234s5363s5366lbl.pdf%23page%3D27&amp;token=Q6Do72axasU76RaY8kGsQEIv5osemX1jeopAlbo3O0hPfv4EqSaajoK%2FXepJwW2xRrtgpdgtwm80Wjp7%2FtA%2FnCKBsGmDGLHgEgm%2FQyJD3p9x3cuxOuqGKzBM1ApFqJAE&amp;TOPIC_ID=9410" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103234s5363s5366lbl.pdf#page=27</a></p>
<p style="text-indent:-2em;margin-left:4em;">Procrit: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F103234s5360s5364lbl.pdf%23page%3D58&amp;token=xFJ8BddpD9cyB11fv7QUlWXUSNSYKMnKJnuMCtUf%2BQkJG8ObiqeL7DMssLDULzlhmzwfQWgsN0pk%2BQPtbXlyw94yWINU3vy6Zu17MVL7JtKksDlIc53V5oFg97jd6zIL&amp;TOPIC_ID=9410" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103234s5360s5364lbl.pdf#page=58</a></p>
<p style="text-indent:-2em;margin-left:4em;">Retacrit (epoetin alfa-epbx): <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F125545s005lbl.pdf%23page%3D31&amp;token=r3dxaDLBrQa92PvbHwYBNM%2FCLNVFy9O7IIwBrHxDRFurfjRSeZmZ1tk9bRveLtZmflp0WUbBN04U9MY79Rz00hRwxjumAG1c1mwb5AvbLGqYTiPzc8%2Bb%2B1mkyqUZDogc&amp;TOPIC_ID=9410" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125545s005lbl.pdf#page=31</a></p></div>
<div class="block use drugH1Div" id="F165741"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anemia due to chemotherapy in patients with cancer:</b> Treatment of anemia in patients with nonmyeloid malignancies in which anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of 2 additional months of planned chemotherapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anemia due to chronic kidney disease:</b> Treatment of anemia due to chronic kidney disease, including patients on dialysis and not on dialysis, to decrease the need for RBC transfusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anemia due to zidovudine in HIV-infected patients:</b> Treatment of anemia due to zidovudine administered at ≤4.2 g/week in HIV-infected patients with endogenous serum erythropoietin levels of ≤500 milliunits/mL.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Reduction of allogeneic RBC transfusion in patients undergoing elective, noncardiac, nonvascular surgery:</b> To reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin &gt;10 to ≤13 g/dL who are at high risk of perioperative blood loss from elective, noncardiac, nonvascular surgery. Epoetin alfa is not indicated for patients who are willing to donate autologous blood preoperatively.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Limitations of use: Epoetin alfa has not been shown to improve quality of life, fatigue, or patient well-being. Epoetin alfa is <b>not</b> indicated for use under the following conditions:</p>
<p style="text-indent:-2em;margin-left:4em;">- Cancer patients receiving hormonal therapy, therapeutic biologic products, or radiation therapy unless also receiving concurrent myelosuppressive chemotherapy</p>
<p style="text-indent:-2em;margin-left:4em;">- Cancer patients receiving myelosuppressive chemotherapy when the expected outcome is curative</p>
<p style="text-indent:-2em;margin-left:4em;">- Cancer patients receiving myelosuppressive chemotherapy when anemia can be managed by transfusion</p>
<p style="text-indent:-2em;margin-left:4em;">- Surgery patients who are willing to donate autologous blood</p>
<p style="text-indent:-2em;margin-left:4em;">- Surgery patients undergoing cardiac or vascular surgery</p>
<p style="text-indent:-2em;margin-left:4em;">- As a substitute for RBC transfusion in patients requiring immediate correction of anemia</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Note:</b> Retacrit (epoetin alfa-epbx) is approved as a biosimilar to Epogen (epoetin alfa) and Procrit (epoetin alfa).</p></div>
<div class="block off-label drugH1Div" id="F25725539"><span class="drugH1">Use: Off-Label: Adult</span><p>Myelodysplastic syndromes, lower-risk (symptomatic anemia management); Red blood cell transfusion refusal (substitute)</p></div>
<div class="block mst drugH1Div" id="F165818"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Epoetin alfa may be confused with darbepoetin alfa, methoxy polyethylene glycol-epoetin beta</p>
<p style="text-indent:-2em;margin-left:4em;">Epogen may be confused with Neupogen</p>
<p style="text-indent:-2em;margin-left:4em;">Procrit may be confused with Retacrit</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Epopen [Spain] may be confused with EpiPen brand name for epinephrine [US, Canada, and multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299274"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6220130"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Hypertension-Associated Agents may enhance the hypertensive effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenalidomide: Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Lenalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovotibeglogene Autotemcel: Erythropoiesis-Stimulating Agents may diminish the therapeutic effect of Lovotibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nandrolone: May enhance the stimulatory effect of Erythropoiesis-Stimulating Agents. Specifically, nandrolone may enhance the erythropoiesis stimulatory effect of Erythropoiesis-Stimulating Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pomalidomide: Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Pomalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: May enhance the adverse/toxic effect of Erythropoiesis-Stimulating Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the hypertensive effect of Hypertension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F165749"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">In vitro studies suggest that recombinant erythropoietin does not cross the human placenta (Reisenberger 1997). Polyhydramnios and intrauterine growth retardation have been reported with use in females with chronic kidney disease (CKD) (adverse effects also associated with maternal disease).</p>
<p style="text-indent:0em;margin-top:2em;">Recombinant erythropoietin alfa has been evaluated as adjunctive treatment for severe pregnancy associated iron deficiency anemia (Breymann 2001; Krafft 2009) and has been used in pregnant females with iron-deficiency anemia associated with CKD (Furaz-Czerpak 2012; Josephson 2007).</p>
<p style="text-indent:0em;margin-top:2em;">Multidose formulations containing benzyl alcohol are contraindicated for use in pregnant females; if treatment during pregnancy is needed, single-dose preparations should be used.</p></div>
<div class="block brc drugH1Div" id="F165750"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Endogenous erythropoietin is found in breast milk (Semba 2002). It is not known if recombinant erythropoietin alfa is present in breast milk. The manufacturer recommends caution be used if the single dose vial preparation is administered to breastfeeding women; use of the multiple dose vials containing benzyl alcohol is contraindicated in breastfeeding women. When administered enterally to neonates (mixed with human milk or infant formula), recombinant erythropoietin did not significantly increase serum EPO concentrations. If passage via breast milk does occur, risk to a breastfed infant appears low (Juul 2003).</p></div>
<div class="block mop drugH1Div" id="F165736"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Transferrin saturation and serum ferritin (prior to and during treatment) to ensure adequate stores before initiating and throughout therapy; Hb (weekly after initiation and following dose adjustments until stable and sufficient to minimize need for RBC transfusion, chronic kidney disease [CKD] patients should be also be monitored at least monthly following Hb stability); BP; monitor for signs of seizures (CKD patients following initiation for first few months, includes new-onset or change in seizure frequency or premonitory symptoms).</p>
<p style="text-indent:-2em;margin-left:2em;">Cancer patients: Examinations recommended prior to treatment include: Appropriate history, physical, and diagnostic tests to identify/rule out other causes of anemia, including peripheral blood smear (in some situations a bone marrow exam may be necessary), assessment (if indicated) for iron, total iron-binding capacity, transferrin saturation, ferritin, folate, vitamin B<sub>12</sub>, or hemoglobinopathy screening, reticulocyte count, kidney function status, and occult blood loss; baseline erythropoietin level; in patients with chronic lymphocytic leukemia, non-Hodgkin lymphoma, or a history of autoimmune disease, direct antiglobulin testing (eg, Coombs test) may be necessary (ASCO/ASH [Bohlius 2019]). During erythropoiesis-stimulating agent (ESA) treatment, assess iron status with total iron-binding capacity, and transferrin saturation or ferritin levels.</p>
<p style="text-indent:-2em;margin-left:2em;">Diabetes: HbA<sub>1c</sub> is not useful as a glycemic indicator in patients treated with an ESA. Other monitoring parameters may be more useful.</p></div>
<div class="block rer drugH1Div" id="F165739"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Myelodysplastic syndromes (off-label use): Patients with baseline erythropoietin levels &gt;500 milliunits/mL are unlikely to respond to erythropoiesis-stimulating agents (ASCO/ASH [Bohlius 2019]).</p>
<p style="text-indent:-2em;margin-left:2em;">Zidovudine-treated HIV patients: Available evidence indicates patients with endogenous serum erythropoietin levels &gt;500 milliunits/mL are unlikely to respond.</p></div>
<div class="block pha drugH1Div" id="F165727"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Epoetin alfa induces erythropoiesis by stimulating the division and differentiation of committed erythroid progenitor cells; induces the release of reticulocytes from the bone marrow into the bloodstream, where they mature to erythrocytes. There is a dose response relationship with this effect. This results in an increase in reticulocyte counts followed by a rise in hematocrit and hemoglobin levels.</p></div>
<div class="block phk drugH1Div" id="F165744"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> While a much higher peak plasma concentration is achieved after IV bolus administration, it declines at a more rapid rate than after subcutaneous administration (McMahon 1990; Salmonson 1990)</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Reticulocyte count increase: Within 10 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Hemoglobin level: 2 to 6 weeks</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: SubQ: Slow (McMahon 1990; Salmonson 1990)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 9 L; rapid in the plasma compartment; concentrated in liver, kidneys, and bone marrow; similar to extracellular plasma volume in adults (McMahon 1990; Salmonson 1990); reported to be higher in premature neonates on body weight basis (Brown 1993)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Some degradation does occur</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SubQ: Premature neonates: 42% (Brown 1993); Adults: 36% (Salmonson 1990); intraperitoneal epoetin alfa: 3% (Macdougall 1989)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: With high doses, nonlinear kinetics have been observed (Wu 2012)</p>
<p style="text-indent:-2em;margin-left:6em;">Anemia of prematurity:</p>
<p style="text-indent:-2em;margin-left:8em;">Post menstrual age (PMA) &lt;32 week (weight: 800 ± 206 grams): IV: 8.1 ± 2.7 hours; SubQ: 7.1 ± 4.1 hours (Brown 1993)</p>
<p style="text-indent:-2em;margin-left:8em;">PMA ≥32 weeks (weight range: 1,330 to 1,740 g): SubQ: Median: 7.9 hours (range: 5.6 to 19.4 hours) (Krishnan 1996)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuroprotective/hypoxic ischemia encephalopathy (HIE) (Wu 2012): ≥36 weeks GA; IV:</p>
<p style="text-indent:-2em;margin-left:8em;">250 units/kg: 7.6 ± 6.9 hours</p>
<p style="text-indent:-2em;margin-left:8em;">500 units/kg: 7.2 ± 1.9 hours</p>
<p style="text-indent:-2em;margin-left:8em;">1,000 units/kg: 15 ± 4.5 hours</p>
<p style="text-indent:-2em;margin-left:8em;">2,500 units/kg: 18.7 ± 4.7 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Chronic kidney disease: IV: 4 to 13 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Cancer: SubQ: 16 to 67 hours; Chronic kidney disease: IV: 4 to 13 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Pediatric patients &gt;1 month and Adults: Chronic kidney disease: SubQ: 5 to 24 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F165751"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Epogen | Eprex | Hemastim | Hemastim p</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Abseamed | Binocrit | Erypo</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Eprex | Recogen</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alfaepoetina humana recombinante | Eprex</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Eprex | Eprex protecs</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Erypro safe | Hemotin epo | Potex 1000 | Potex 10000 | Potex 2000 | Potex 3000 | Potex 4000 | Vintor</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Eprex</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Epiao | Espo</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Eprex | Eritromax | Eritropoyetina | Hemotin epo</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Binocrit</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Abseamed | Binocrit | Eprex | Erypo</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Epocass | Hemotin epo | Wepox</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Epogen</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Eprex</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Epiao | Eprex | Espogen</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Epopen | Eprex</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Abseamed | Eprex</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Eprex</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Abseamed | Binocrit | Epoetin alfa hexal | Eprex</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Eprex</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Epodion | Eprex | Erykine | Hemapo | Renogen</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Eprex</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Anfoe | Ceriton | Epofer | Epofit | Eposis | Eposure | Epotop | Epotrend | Epotrust | Epox | Eprex | Erykine | Erypeg | Erypro | Erypro safe | Esa | Espogen | Lg espogen | Relipoietin | Renocel | Repomia | Vintor | Wepox</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Abseamed | Binocrit | Epoetina alfa | Eprex | Globuren</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Epoetin alfa bs | Espo kirin | Espo sankyo</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Epofit | Eprex | Erypro safe | Relipoietin | Vintor</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Epokine | Eposis | Epotin plus | Eprex | Espogen</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Eprex</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Eprex</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Eprex</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alveritin | Eprex</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Abseamed | Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Eprex</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Epoetina alfa | Ior epocim | Proclat Alfa</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Dypotin | Epocare | Epogen | Epokine | Epolitt | Epotin | Epovax | Eprex | Hemapo | Renogen | Wepox</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Epiao | Epocan | Epokine | Epotiv | Eprex | PDpoetin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Abseamed | Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Epogen | Procrit</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Eritromax | Relipoietin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Epotin | Eprex</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Epoetin alfa hexal | Epokine | Eprex</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Aeprin | Binocrit | Eprex | Eralfon</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Eprex</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Abseamed | Binocrit | Eprex</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Epiao | Epoetin | Epokine | Eposis | Eprex | Eritine | Eritromax | Erypo | Espogen | Hema plus</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Epomax | Ior epocim</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Dropoetin | Epoplus | Eprex</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Eprex</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Binocrit | Emavail | Epobiocrin | Epoetin | Epovitan af | Shanpoetin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Wepox</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Epocass | Epotiv | Eprex | Eritromax</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Espro eritrop</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Nanokine</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Eprex</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Vintor | Wepox</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-24760628">
<a name="24760628"></a>Aher SM, Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.<i> Cochrane Database Syst Rev</i>. 2014;4:CD004868.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/24760628/pubmed" id="24760628" target="_blank">24760628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18956998">
<a name="18956998"></a>Ball AM, Winstead PS. Recombinant human erythropoietin therapy in critically ill Jehovah's Witnesses. <i>Pharmacotherapy</i>. 2008;28(11):1383-1390. doi:10.1592/phco.28.11.1383.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/18956998/pubmed" id="18956998" target="_blank">18956998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berns.2">
<a name="Berns.2"></a>Berns JS, Qunibi WY. Treatment of anemia in patients on dialysis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 7, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berns.1">
<a name="Berns.1"></a>Berns JS. Treatment of anemia in nondialysis chronic kidney disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 7, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2488207">
<a name="2488207"></a>Boelaert JR, Schurgers ML, Matthys EG, et al. Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients. <i>Perit Dial Int</i>. 1989;9(2):95-98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/2488207/pubmed" id="2488207" target="_blank">2488207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30969847">
<a name="30969847"></a>Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. <i>J Clin Oncol</i>. 2019;37(15):1336-1351. doi: 10.1200/JCO.18.02142.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/30969847/pubmed" id="30969847" target="_blank">30969847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11262469">
<a name="11262469"></a>Breymann C, Visca E, Huch R, et al. Efficacy and Safety of Intravenously Administered Iron Sucrose With and Without Adjuvant Recombinant Human Erythropoietin for the Treatment of Resistant Iron-Deficiency Anemia During Pregnancy. <i>Am J Obstet Gynecol</i>. 2001;184(4):662-667.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/11262469/pubmed" id="11262469" target="_blank">11262469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8463922">
<a name="8463922"></a>Brown MS, Jones MA, Ohls RK, Christensen RD. Single-dose pharmacokinetics of recombinant human erythropoietin in preterm infants after intravenous and subcutaneous administration. <i>J Pediatr</i>. 1993;122(4):655-657.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/8463922/pubmed" id="8463922" target="_blank">8463922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26518969">
<a name="26518969"></a>Brunetta DM, Kaufman J, De Santis GC, et al. Severe Acute Anemia After Liver Transplantation in an Elderly Jehovah's Witness Treated With High-dose Erythropoietin and Ferric Carboxymaltose: A Case Report. <i>Transplant Proc</i>. 2015 Oct;47(8):2548-51. doi:10.1016/j.transproceed.2015.09.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/26518969/pubmed" id="26518969" target="_blank">26518969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17687059">
<a name="17687059"></a>Cohen V, Jellinek SP, Teperikidis L, et al. Room-temperature storage of medications labeled for refrigeration. <i>Am J Health-Syst Pharm</i>. 2007;64(16):1711-1715.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/17687059/pubmed" id="17687059" target="_blank">17687059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1529989">
<a name="1529989"></a>Corbo DC, Suddith RL, Sharma B, Naso RB. Stability, potency, and preservative effectiveness of epoetin alfa after addition of a bacteriostatic diluent. <i>Am J Hosp Pharm</i>. 1992;49(6):1455-1458.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/1529989/pubmed" id="1529989" target="_blank">1529989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30675430">
<a name="30675430"></a>Coyne DW, Goldsmith D, Macdougall IC. New options for the anemia of chronic kidney disease. <i>Kidney Int Suppl (2011)</i>. 2017;7(3):157-163. doi:10.1016/j.kisu.2017.09.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/30675430/pubmed" id="30675430" target="_blank">30675430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25974419">
<a name="25974419"></a>Dallas T, Welsby I, Bottiger B, Milano C, Daneshmand M, Guinn N. Bloodless Orthotopic Heart Transplantation in a Jehovah's Witness. <i>A A Case Rep</i>. 2015;4(10):140-142. doi:10.1213/XAA.0000000000000067.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/25974419/pubmed" id="25974419" target="_blank">25974419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20385632">
<a name="20385632"></a>Elmahdy H, El-Mashad AR, El-Bahrawy H, et al, "Human Recombinant Erythropoietin in Asphyxia Neonatorum: Pilot Trial," <i>Pediatrics</i>, 2010, 125(5):1135-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/20385632/pubmed" id="20385632" target="_blank">20385632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Epogen.1">
<a name="Epogen.1"></a>Epogen (epoetin alfa) [prescribing information]. Thousand Oaks, CA: Amgen; July 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eprex.1">
<a name="Eprex.1"></a>Eprex (epoetin alfa) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29895954">
<a name="29895954"></a>Fenaux P, Santini V, Spiriti MAA, et al. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. <i>Leukemia</i>. 2018;32(12):2648-2658. doi: 10.1038/s41375-018-0118-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/29895954/pubmed" id="29895954" target="_blank">29895954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11828859">
<a name="11828859"></a>Ferri RS, Adinolfi A, Orsi AJ, et al. Treatment of anemia in patients with HIV infection--part 2: guidelines for management of anemia. <i>J Assoc Nurses AIDS Care</i>. 2002;13(1):50-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/11828859/pubmed" id="11828859" target="_blank">11828859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29336855">
<a name="29336855"></a>Fishbane S, Spinowitz B. Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018. <i>Am J Kidney Dis</i>. 2018;71(3):423-435. doi:10.1053/j.ajkd.2017.09.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/29336855/pubmed" id="29336855" target="_blank">29336855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22508145">
<a name="22508145"></a>Furaz-Czerpak KR, Fernández-Juárez G, Moreno-de la Higuera MÁ, et al, "Pregnancy in Women on Chronic Dialysis: A Review," <i>Nefrologia</i>, 2012, 32(3):287-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/22508145/pubmed" id="22508145" target="_blank">22508145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19564636">
<a name="19564636"></a>Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). <i>Blood</i>. 2009;114(12):2393-2400.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/19564636/pubmed" id="19564636" target="_blank">19564636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1691780">
<a name="1691780"></a>Halperin DS, Wacker P, Lacourt G, et al, “Effects of Recombinant Human Erythropoietin in Infants With the Anemia of Prematurity: A Pilot Study,” <i>J Pediatr</i>, 1990, 116(5):779-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/1691780/pubmed" id="1691780" target="_blank">1691780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7833279">
<a name="7833279"></a>Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. <i>Br J Haematol</i>. 1995;89(1):67-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/7833279/pubmed" id="7833279" target="_blank">7833279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19903808">
<a name="19903808"></a>Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. <i>J Natl Cancer Inst</i>. 2009;101(23):1633-1641. doi:10.1093/jnci/djp387.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/19903808/pubmed" id="19903808" target="_blank">19903808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. 2018. Available at <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-arv/guidelines-pediatric-arv.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-arv/guidelines-pediatric-arv.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313. doi:10.1034/j.1600-0536.2002.4705104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18827697">
<a name="18827697"></a>Joseph SA Jr, Berekashvili K, Mariller MM, et al. Blood conservation techniques in spinal deformity surgery: a retrospective review of patients refusing blood transfusion. <i>Spine (Phila Pa 1976)</i>. 2008;33(21):2310-2315. doi:10.1097/BRS.0b013e31818047f2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/18827697/pubmed" id="18827697" target="_blank">18827697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17395118">
<a name="17395118"></a>Josephson MA and McKay DB, "Considerations in the Medical Management of Pregnancy in Transplant Recipients, <i>Adv Chronic Kidney Dis</i>, 2007, 14(2):156-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/17395118/pubmed" id="17395118" target="_blank">17395118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12773061">
<a name="12773061"></a>Juul SE, Christensen RD. Absorption of enteral recombinant human erythropoietin by neonates. <i>Ann Pharmacother</i>. 2003;37(6):782-786. doi:10.1345/aph.1C428<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/12773061/pubmed" id="12773061" target="_blank">12773061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31940698">
<a name="31940698"></a>Juul SE, Comstock BA, Wadhawan R, et al. A randomized trial of erythropoietin for neuroprotection in preterm infants. <i>N Engl J Med</i>. 2020;382(3):233-243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/31940698/pubmed" id="31940698" target="_blank">31940698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18676557">
<a name="18676557"></a>Juul SE, McPherson RJ, Bauer LA, et al, "A Phase I/II Trial of High-Dose Erythropoietin in Extremely Low Birth Weight Infants: Pharmacokinetics and Safety," <i>Pediatrics</i>, 2008, 122(2):383-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/18676557/pubmed" id="18676557" target="_blank">18676557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27209352">
<a name="27209352"></a>Kang J, Park J, Lee JM, Park JJ, Choi DJ. The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: A meta-analysis of randomized clinical trials. <i>Int J Cardiol</i>. 2016;218:12-22. doi:10.1016/j.ijcard.2016.04.187<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/27209352/pubmed" id="27209352" target="_blank">27209352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17720528">
<a name="17720528"></a>KDOQI, "KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target," <i>Am J Kidney Dis</i>, 2007, 50(3):471-530.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/17720528/pubmed" id="17720528" target="_blank">17720528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kenner.1">
<a name="Kenner.1"></a>Kenner C, Wright Litt J, eds. <i>Comprehensive Noenatal Care: An Interdisciplinary Approach</i>. Elsevier Health Sciences; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. <i>Kidney Int Suppl</i>. 2012;2(suppl):279-335. https://kdigo.org/guidelines/anemia-in-ckd/. Published August 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2505184">
<a name="2505184"></a>Kindler J, Eckardt KU, Ehmer B, et al. Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure. <i>Nephrol Dial Transplant</i>. 1989;4(5):345-349. doi:10.1093/oxfordjournals.ndt.a091888<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/2505184/pubmed" id="2505184" target="_blank">2505184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27120597">
<a name="27120597"></a>Kobayashi H, Abe M, Yoshida Y, Suzuki H, Maruyama N, Okada K. Glycated albumin versus glycated hemoglobin as a glycemic indicator in diabetic patients on peritoneal dialysis. <i>Int J Mol Sci</i>. 2016;17(5):619. doi:10.3390/ijms17050619<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/27120597/pubmed" id="27120597" target="_blank">27120597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19506383">
<a name="19506383"></a>Krafft A, Bencaiova G, and Breymann C, "Selective Use of Recombinant Human Erythropoietin in Pregnant Patients With Severe Anemia or Nonresponsive to Iron Sucrose Alone," <i>Fetal Diagn Ther</i>, 2009, 25(2):239-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/19506383/pubmed" id="19506383" target="_blank">19506383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8894079">
<a name="8894079"></a>Krishnan R, Shankaran S, Krishnan M, Kauffman RE, Kumar P, Lucena J. Pharmacokinetics of erythropoietin following single-dose subcutaneous administration in preterm infants. <i>Biol Neonate</i>. 1996;70(3):135-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/8894079/pubmed" id="8894079" target="_blank">8894079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2563798">
<a name="2563798"></a>Macdougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA, Williams JD. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. <i>Lancet</i>. 1989;1(8635):425-427. doi:10.1016/s0140-6736(89)90014-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/2563798/pubmed" id="2563798" target="_blank">2563798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2029809">
<a name="2029809"></a>Macdougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). <i>Clin Pharmacokinet</i>. 1991;20(2):99-113. doi:10.2165/00003088-199120020-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/2029809/pubmed" id="2029809" target="_blank">2029809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8139627">
<a name="8139627"></a>Maier RF, Obladen M, Scigalla P, et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. European Multicentre Erythropoietin Study Group. <i>N Engl J Med</i>. 1994;330(17):1173-1178.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/8139627/pubmed" id="8139627" target="_blank">8139627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24809815">
<a name="24809815"></a>McCartney S, Guinn N, Roberson R, et al. Jehovah's Witnesses and cardiac surgery: a single institution's experience. <i>Transfusion</i>. 2014;54(10 Pt 2):2745-2752. doi:10.1111/trf.12696.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/24809815/pubmed" id="24809815" target="_blank">24809815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18417741">
<a name="18417741"></a>McGowan T, Vaccaro NM, Beaver JS, Massarella J, Wolfson M. Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. <i>Clin J Am Soc Nephrol</i>. 2008;3(4):1006-1014. doi: 10.2215/CJN.05671207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/18417741/pubmed" id="18417741" target="_blank">18417741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2224121">
<a name="2224121"></a>McMahon FG, Vargas R, Ryan M, Jain AK, Abels RI, Perry B, Smith IL. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injection in healthy volunteers. <i>Blood</i>. 1990;76(9):1718-1722.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/2224121/pubmed" id="2224121" target="_blank">2224121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28456387">
<a name="28456387"></a>Mulkey SB, Ramakrishnaiah RH, McKinstry RC, et al. Erythropoietin and brain magnetic resonance imaging findings in hypoxic-ischemic encephalopathy: volume of acute brain injury and 1-year neurodevelopmental outcome. <i>J Pediatr</i>. 2017;186:196-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/28456387/pubmed" id="28456387" target="_blank">28456387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12846896">
<a name="12846896"></a>Musto P, Falcone A, Sanpaolo G, et al. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. <i>Br J Haematol</i>. 2003;122(2):269-271. doi: 10.1046/j.1365-2141.2003.04435.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/12846896/pubmed" id="12846896" target="_blank">12846896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27187300">
<a name="27187300"></a>Natalucci G, Latal B, Koller B, et al. Effect of early prophylactic high-dose recombinant human erythropoietin in very preterm infants on neurodevelopmental outcome at 2 years: a randomized clinical trial. <i>JAMA</i>. 2016;315(19):2079-2085.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/27187300/pubmed" id="27187300" target="_blank">27187300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11229970">
<a name="11229970"></a>National Kidney Foundation (NKF). K/DOQI clinical practice guidelines for anemia of chronic kidney disease, 2000. <i>Am J Kidney Dis</i>. 2001;37(1)(suppl 1):S182-S238. doi:10.1016/s0272-6386(01)70008-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/11229970/pubmed" id="11229970" target="_blank">11229970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12635452">
<a name="12635452"></a>Naughton CA, Duppong LM, Forbes KD, Sehgal I. Stability of multidose, preserved formulation epoetin alfa in syringes for three and six weeks. <i>Am J Health Syst Pharm</i>. 2003;60(5):464-468.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/12635452/pubmed" id="12635452" target="_blank">12635452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20437563">
<a name="20437563"></a>Neubauer AP, Voss W, Wachtendorf M, et al, "Erythropoietin Improves Neurodevelopmental Outcome of Extremely Preterm Infants," <i>Ann Neurol</i>, 2010, 67(5):657-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/20437563/pubmed" id="20437563" target="_blank">20437563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8740324">
<a name="8740324"></a>Ohls RK, Christensen RD. Stability of human recombinant epoetin alfa in commonly used neonatal intravenous solutions. <i>Ann Pharmacother</i>. 1996;30(5):466-468.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/8740324/pubmed" id="8740324" target="_blank">8740324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9403642">
<a name="9403642"></a>Ohls RK, Harcum J, Schibler KR, Christensen RD. The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double-blind, placebo-controlled study. <i>J Pediatr</i>. 1997;131(5):661-665.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/9403642/pubmed" id="9403642" target="_blank">9403642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22137666">
<a name="22137666"></a>Ohls RK, Roohi M, Peceny HM, Schrader R, Bierer R. A randomized, masked study of weekly erythropoietin dosing in preterm infants. <i>J Pediatr</i>. 2012;160(5):790-795.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/22137666/pubmed" id="22137666" target="_blank">22137666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24771408">
<a name="24771408"></a>Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.<i> Database Syst Rev</i>. 2014;4:CD004863.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/24771408/pubmed" id="24771408" target="_blank">24771408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29145693">
<a name="29145693"></a>Ohlsson A, Aher SM. Early erythropoiesis-stimulating agents in preterm or low birth weight infants. <i>Cochrane Database Syst Rev</i>. 2017;11(11):CD004863.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/29145693/pubmed" id="29145693" target="_blank">29145693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17940203">
<a name="17940203"></a>Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. <i>Blood</i>. 2008;111(2):574-582.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/17940203/pubmed" id="17940203" target="_blank">17940203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30549002">
<a name="30549002"></a>Park S, Greenberg P, Yucel A, et al. Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review.<i> Br J Haematol</i>. 2019;184(2):134-160. doi: 10.1111/bjh.15707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/30549002/pubmed" id="30549002" target="_blank">30549002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8808454">
<a name="8808454"></a>Petersen J, Kang MS, Hays MT. Erythropoietin can be administered during dialysis. A kinetic analysis. <i>ASAIO J</i>. 1996;42(1):27-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/8808454/pubmed" id="8808454" target="_blank">8808454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12455725">
<a name="12455725"></a>Piccoli A, Malagoli A, Komninos G, Pastori G. Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia. <i>J Nephrol</i>. 2002;15(5):565-574.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/12455725/pubmed" id="12455725" target="_blank">12455725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27132333">
<a name="27132333"></a>Plunkett H, Gass H, Gross R. Intraoperative Blood Loss Among Jehovah's Witnesses in Spinal Deformity Surgery: A Report of 5 Cases. <i>J S C Med Assoc</i>. 2015;111(2):59-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/27132333/pubmed" id="27132333" target="_blank">27132333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Procrit.1">
<a name="Procrit.1"></a>Procrit (epoetin alfa) [prescribing information]. Horsham, PA: Janssen; July 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16114787">
<a name="16114787"></a>Provenzano R, Bhaduri S, Singh AK; PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. <i>Clin Nephrol</i>. 2005;64(2):113-123.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/16114787/pubmed" id="16114787" target="_blank">16114787</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15224803">
<a name="15224803"></a>Provenzano R, Garcia-Mayol L, Suchinda P, et al; POWER Study Group. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. <i>Clin Nephrol</i>. 2004;61(6):392-405.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/15224803/pubmed" id="15224803" target="_blank">15224803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24297193">
<a name="24297193"></a>Qaseem A, Humphrey LL, Fitterman N, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Treatment of anemia in patients with heart disease: a clinical practice guideline from the American college of physicians. <i>Ann Intern Med</i>. 2013;159(11):770-779.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/24297193/pubmed" id="24297193" target="_blank">24297193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28407666">
<a name="28407666"></a>Rasche FM, Ebert T, Beckmann J, et al. Influence of erythropoiesis-stimulating agents on HbA1c and fructosamine in patients with haemodialysis. <i>Exp Clin Endocrinol Diabetes</i>. 2017;125(6):384-391. doi:10.1055/s-0042-124577<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/28407666/pubmed" id="28407666" target="_blank">28407666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26031262">
<a name="26031262"></a>Rebel A, Beck A, Efron P, Bavry AA, Ang D. Successful Rescue Therapy for Severe Acute Anemia: Managing the Critically Ill Jehovah's Witness. <i>Am Surg</i>. 2015;81(6):E263-265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/26031262/pubmed" id="26031262" target="_blank">26031262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9166312">
<a name="9166312"></a>Reisenberger K, Egarter C, Kapiotis S, et al, "Transfer of Erythropoietin Across the Placenta Perfused <i>in vitro</i>," <i>Obstet Gynecol</i>, 1997, 89(5 Pt 1):738-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/9166312/pubmed" id="9166312" target="_blank">9166312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Retacrit.1">
<a name="Retacrit.1"></a>Retacrit (epoetin alfa-epbx) [prescribing information]. Lake Forest, IL: Hospira Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20975064">
<a name="20975064"></a>Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. <i>J Clin Oncol</i>. 2010;28(33):4996-5010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/20975064/pubmed" id="20975064" target="_blank">20975064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2378790">
<a name="2378790"></a>Salmonson T, Danielson BG, and Wikstrom B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. <i>Br J Clin Pharmac</i>. 1990; 29:709-713.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/2378790/pubmed" id="2378790" target="_blank">2378790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12192960">
<a name="12192960"></a>Semba RD and Juul SE, "Erythropoietin in Human Milk: Physiology and Role in Infant Health," <i>J Hum Lact</i>, 2002, 18(3):252-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/12192960/pubmed" id="12192960" target="_blank">12192960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7770284">
<a name="7770284"></a>Shannon KM, Keith JF 3rd, Mentzer WC, et al, “Recombinant Human Erythropoietin Stimulates Erythropoiesis and Reduces Erythrocyte Transfusions in Very Low Birth Weight Preterm Infants,” <i>Pediatrics</i>, 1995, 95(1):1-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/7770284/pubmed" id="7770284" target="_blank">7770284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2926567">
<a name="2926567"></a>Sinai-Trieman L, Salusky IB, and Fine RN, “Use of Subcutaneous Recombinant Human Erythropoietin in Children Undergoing Continuous Cycling Peritoneal Dialysis,” <i>J Pediatr</i>, 1989, 114(4 Pt 1):550-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/2926567/pubmed" id="2926567" target="_blank">2926567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17108343">
<a name="17108343"></a>Singh AJ, Szczech L, Tang Kl, et al, “Correction of Anemia With Epoetin Alfa in Chronic Kidney Disease,” <i>N Engl J Med</i>, 2006, 355(20):2085-98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/17108343/pubmed" id="17108343" target="_blank">17108343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17462454">
<a name="17462454"></a>Society of Thoracic Surgeons Blood Conservation Guideline Task Force and Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion, “Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline,” <i>Ann Thorac Surg</i>, 2007, 83(5 Suppl):27-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/17462454/pubmed" id="17462454" target="_blank">17462454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1353044">
<a name="1353044"></a>Society of Thoracic Surgeons Blood Conservation Guideline Task Force. Ferraris VA, Brown JR, Despotis GJ, et al.; Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion. Shore-Lesserson LJ, Goodnough LT, Mazer CD, et al.; International Consortium for Evidence Based Perfusion. Baker RA, Dickinson TA, FitzGerald DJ, Likosky DS, Shann KG. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. <i>Ann Thorac Surg</i>. 2011;91(3):944-982. doi:10.1016/j.athoracsur.2010.11.078.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/1353044/pubmed" id="1353044" target="_blank">1353044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27130143">
<a name="27130143"></a>Song J, Sun H, Xu F, et al. Recombinant human erythropoietin improves neurological outcomes in very preterm infants. <i>Ann Neurol</i>. 2016;80(1):24-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/27130143/pubmed" id="27130143" target="_blank">27130143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23473338">
<a name="23473338"></a>Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. <i>N Engl J Med</i>. 2013;368(13):1210-1219. doi:10.1056/NEJMoa1214865<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/23473338/pubmed" id="23473338" target="_blank">23473338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26211405">
<a name="26211405"></a>Tanaka A, Ota T, Uriel N, et al. Cardiovascular surgery in Jehovah's Witness patients: The role of preoperative optimization. <i>J Thorac Cardiovasc Surg</i>. 2015;150(4):976-983.e1-3. doi:10.1016/j.jtcvs.2015.06.059.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/26211405/pubmed" id="26211405" target="_blank">26211405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23008465">
<a name="23008465"></a>Wu YW, Bauer LA, Ballard RA, et al. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. <i>Pediatrics</i>. 2012;130(4):683-691. doi:10.1542/peds.2012-0498.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/23008465/pubmed" id="23008465" target="_blank">23008465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27244862">
<a name="27244862"></a>Wu YW, Mathur AM, Chang T, et al. High-dose erythropoietin and hypothermia for hypoxic-ischemic encephalopathy: a phase II trial. <i>Pediatrics</i>. 2016;137(6):e20160191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/27244862/pubmed" id="27244862" target="_blank">27244862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19651565">
<a name="19651565"></a>Zhu C, Kang W, Xu F, et al, "Erythropoietin Improved Neurologic Outcomes in Newborns With Hypoxic-Ischemic Encephalopathy," <i>Pediatrics</i>, 2009, 124(2):e218-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epoetin-alfa-including-biosimilars-drug-information/abstract-text/19651565/pubmed" id="19651565" target="_blank">19651565</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9410 Version 299.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
